BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gain Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Gain Therapeutics\, Inc.'s drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07280299-1640@assetmemo.bio
DTSTAMP:20261121T005943Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:GT-02287: Phase 2 readout est. (NCT07280299)
DESCRIPTION:GT-02287\, phase 2\, Parkinson's Disease.\nStudy: Efficacy\, Sa
 fety\, Tolerability\, and Biomarker Effects of GT-02287 in Early Parkinson
 's Disease\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gt-02287#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07280299
URL:https://assetmemo.bio/drug/gt-02287#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
